Catalyst Pharmaceuticals (CPRX) Given a $8.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald set a $8.00 target price on Catalyst Pharmaceuticals (NASDAQ:CPRX) in a report released on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

CPRX has been the topic of a number of other research reports. BidaskClub cut shares of Catalyst Pharmaceuticals from a sell rating to a strong sell rating in a research report on Wednesday, August 8th. HC Wainwright set a $6.00 target price on shares of Catalyst Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 22nd. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a hold rating to a buy rating and set a $3.25 target price on the stock in a research report on Monday, August 13th. Finally, Oppenheimer set a $6.00 target price on shares of Catalyst Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, October 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $5.61.

Shares of Catalyst Pharmaceuticals stock traded down $0.06 on Friday, hitting $3.12. 1,251,582 shares of the company traded hands, compared to its average volume of 874,241. The stock has a market cap of $326.27 million, a P/E ratio of -14.86 and a beta of 1.46. Catalyst Pharmaceuticals has a 12-month low of $2.18 and a 12-month high of $4.51.



Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. On average, equities research analysts forecast that Catalyst Pharmaceuticals will post -0.29 EPS for the current year.

Large investors have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. increased its position in shares of Catalyst Pharmaceuticals by 24.3% in the first quarter. Schwab Charles Investment Management Inc. now owns 184,904 shares of the biopharmaceutical company’s stock valued at $442,000 after acquiring an additional 36,200 shares during the period. Northern Trust Corp increased its position in shares of Catalyst Pharmaceuticals by 22.5% in the first quarter. Northern Trust Corp now owns 1,009,947 shares of the biopharmaceutical company’s stock valued at $2,414,000 after acquiring an additional 185,639 shares during the period. BlackRock Inc. increased its position in shares of Catalyst Pharmaceuticals by 16.9% in the first quarter. BlackRock Inc. now owns 4,698,531 shares of the biopharmaceutical company’s stock valued at $11,230,000 after acquiring an additional 678,950 shares during the period. New York State Common Retirement Fund increased its position in shares of Catalyst Pharmaceuticals by 47.6% in the first quarter. New York State Common Retirement Fund now owns 74,994 shares of the biopharmaceutical company’s stock valued at $179,000 after acquiring an additional 24,200 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in shares of Catalyst Pharmaceuticals in the first quarter valued at about $230,000. Institutional investors own 51.49% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Further Reading: Relative Strength Index

Analyst Recommendations for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply